TCR-engineered T Cells in Solid Tumors: IMA202-101

NCT03441100 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Refractory Cancer
Recurrent Cancer
Cancer

Interventions

DRUG: IMA202 Product
DEVICE: IMADetect®

Sponsor

Immatics US, Inc.